<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04104503</url>
  </required_header>
  <id_info>
    <org_study_id>18153A</org_study_id>
    <nct_id>NCT04104503</nct_id>
  </id_info>
  <brief_title>A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects</brief_title>
  <official_title>Interventional, Open-label, Two-part, Partly-randomized Study Investigating the Pharmacokinetic Properties, Absolute Bioavailability, Food Effect, and Intra-subject Variability of up to 5 Prototype Modified-release Tablet Formulations of Lu AF11167 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the extent to which Lu AF11167 enters the
      bloodstream following tablet intake and the influence of food on uptake in healthy men and
      women
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be split into Part A and Part B. Part A will happen first and will look at
      new tablet formulations of the test medicine compared to a previously known formulation
      (reference tablet). The results from Part A of the study will be used to decide which
      formulation will be tested in Part B of the study. Part B of the study will look at the food
      effect, variability between participants, and absolute bioavailability of the test medicine
      i.e. how much of the test medicine is taken up by the body when dosed by mouth compared to
      when dosed once by injection directly into the vein. Safety and tolerability will be assessed
      throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Actual">April 9, 2020</completion_date>
  <primary_completion_date type="Actual">April 9, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Lu AF11167</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf) of Lu AF11167</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>Area under the plasma concentration time curve from zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative bioavailability F(rel) of Lu AF11167</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>F(rel) is estimated as the dose normalized AUC(inf) for the test formulation relative to the reference formulation (part A only)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute bioavailability F(abs) of Lu AF11167</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>F(abs) is estimated as the dose normalized AUC(inf) for the test formulation relative to the intravenous reference formulation (part B only)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment period 1: Fasted + iv;
Treatment period 2: Fasted;
Treatment period 3: High-fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment period 1: High-fat meal;
Treatment period 2: Fasted + iv;
Treatment period 3: Fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment period 1: Fasted;
Treatment period 2: High-fat meal;
Treatment period 3: Fasted + iv</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF11167</intervention_name>
    <description>Lu AF11167 - 2 mg modified release tablets (reference formulation), up to 5 prototype MR tablet formulations (test formulations)</description>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-Lu AF11167</intervention_name>
    <description>single iv microdose administered as a 15 minutes infusion</description>
    <arm_group_label>Part B group 1</arm_group_label>
    <arm_group_label>Part B group 2</arm_group_label>
    <arm_group_label>Part B group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation)</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>Part B group 1</arm_group_label>
    <arm_group_label>Part B group 2</arm_group_label>
    <arm_group_label>Part B group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) of ≥18.5 and ≤30.0 kg/m2

          -  (Part B only) Women of child-bearing potential will have a confirmed non-pregnant and
             non-lactating status

        Exclusion Criteria:

          -  The subject has any concurrent disorder that may affect the particular target or
             absorption, distribution, or elimination of the investigational medical product

        Other in- and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

